Edition:
United Kingdom

Merus NV (MRUS.OQ)

MRUS.OQ on NASDAQ Stock Exchange Global Market

22.06USD
22 Jun 2018
Change (% chg)

$-0.41 (-1.82%)
Prev Close
$22.47
Open
$22.71
Day's High
$22.97
Day's Low
$21.25
Volume
15,508
Avg. Vol
10,635
52-wk High
$22.97
52-wk Low
$13.34

Chart for

About

Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets... (more)

Overall

Beta: --
Market Cap(Mil.): $404.73
Shares Outstanding(Mil.): 19.39
Dividend: --
Yield (%): --

Financials

  MRUS.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -6.12 -- --
ROI: -58.10 2.00 14.38
ROE: -113.41 3.49 16.08

BRIEF-Merus Q4 Loss Per Share EUR 0.73

* MERUS ANNOUNCES RECENT CORPORATE DEVELOPMENTS AND FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2017

26 Apr 2018

BRIEF-Merus And Vall d'Hebron Institute Of Oncology Announce Research Collaboration

* MERUS AND VALL D'HEBRON INSTITUTE OF ONCOLOGY ANNOUNCE RESEARCH COLLABORATION TO DEVELOP INNOVATIVE BISPECIFIC ANTIBODIES FOR THERAPEUTIC APPLICATIONS IN TREATMENT OF CANCER Source text for Eikon: Further company coverage:

20 Mar 2018

BRIEF-Merus Says Ono Pharma Exercised Option For New Research And License Agreement

* MERUS ANNOUNCES ONO PHARMACEUTICALS EXERCISE OF ITS OPTION FOR NEW RESEARCH AND LICENSE AGREEMENT TO GENERATE BISPECIFIC ANTIBODY TARGETING AUTOIMMUNE DISEASES

14 Mar 2018

BRIEF-Merus Announces $55.8 Mln Private Placement Offering

* MERUS ANNOUNCES $55.8 MILLION PRIVATE PLACEMENT OFFERING OF COMMON STOCK

14 Feb 2018

BRIEF-Merus Provides Clinical Updates For Mcla-117 And Mcla-158 Programs

* MERUS PROVIDES CLINICAL UPDATES FOR MCLA-117 AND MCLA-158 PROGRAMS

04 Jan 2018

Earnings vs. Estimates